Roles
- Assistant Professor of Urology
- Associate Program Director of Urologic Oncology Fellowship
-
Biography
Dr. Ali Mouzannar is an Assistant Professor of Urologic Oncology at the Desai Sethi Urology Institute, University of Miami Health System, and Associate Program Director of the SUO-accredited Urologic Oncology Fellowship. He provides comprehensive, multidisciplinary care for prostate, bladder, and kidney cancers, with advanced expertise in robotic and open oncologic surgery. His surgical practice includes radical prostatectomy, partial and radical nephrectomy, radical cystectomy, and retroperitoneal lymph node dissection (RPLND)—delivering durable cancer control while preserving quality of life.
Dr. Mouzannar maintains an active clinical trials program and serves as Principal Investigator on investigator-initiated, cooperative group, and industry-sponsored studies. His research focuses on non–muscle invasive bladder cancer, biomarker-guided therapy selection, and novel intravesical and systemic treatments. He also conducts work exploring how artificial intelligence and machine learning can advance surgical education, performance assessment, and outcomes. His academic contributions include peer-reviewed publications and book chapters, and he serves as a reviewer for scientific journals.
Trained at Memorial Sloan Kettering Cancer Center (urologic oncology fellowship, 2024) following University of Miami urology residency (2022), Dr. Mouzannar integrates evidence-driven care, complex surgical capability, and access to clinical trials—helping patients and referring physicians navigate challenging decisions with clarity and confidence. -
Education & Training
Education
Post Graduate Training
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 3 clinical trials.
-
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)
- Principal Investigator: Ali Mouzannar
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
To evaluate the recurrence free survival (RFS) of transurethral resection of bladder tumor (TURBT) followed by cretostimogene versus TURBT followed by observation in participants with intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC). To evaluate the RFS at 12 months and 24 months. To assess the efficacy of treatment based on Coxsackie-Adenovirus Receptor (CAR) and E2F transcription factor levels in tumor tissue
- Principal Investigator: Ali Mouzannar
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
- Principal Investigator: Ali Mouzannar
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
